Advances in targeted dendrimers for cancer therapy and challenges for clinical translation

Silva, João Vitor; Santos, Soraya da Silva; Sanches, Luccas Missfeldt; Ferreira, Elizabeth Igne; Giarolla, Jeanine

doi:10.1016/b978-0-12-821250-9.00003-2

Cited by 2 publications

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A wide variety of materials such as polymeric material [ 7 , 8 , 9 ], dendrimers [ 10 ], liposomes [ 5 , 11 , 12 , 13 , 14 ], magnetic nanoparticles [ 13 ], or graphene-based materials [ 15 , 16 , 17 ] have been proposed as a drug carrier to deliver anticancer drugs. Since it can be loaded with various anticancer drugs and can load both hydrophilic and hydrophobic pharmaceutical agents, graphene oxide (GO), a family of graphene-based material derivatives, is one of the potential novel drug delivery systems that is being developed widely.…”

Section: Introductionmentioning

confidence: 99%

Magnetic Graphene-Based Nanosheets with Pluronic F127-Chitosan Biopolymers Encapsulated α-Mangosteen Drugs for Breast Cancer Cells Therapy

Hardiansyah¹,

Randy²,

Dewi³

et al. 2022

Polymers

View full text Add to dashboard Cite

In this study, multifunctional chitosan-pluronic F127 with magnetic reduced graphene oxide (MRGO) nanocomposites were developed through the immobilization of chitosan and an amphiphilic polymer (pluronic F127) onto the MRGO. Physicochemical characterizations and in-vitro cytotoxicity of nanocomposites were investigated through field emission scanning electron microscopy (FESEM), X-ray diffraction (XRD), Fourier-transform infrared (FTIR) spectroscopy, particle size analysis, vibrating sample magnetometer, Raman spectroscopy and resazurin-based in-vitro cytotoxicity assay. FESEM observation shows that the magnetic nanoparticles could tethered on the surface of MRGO, promoting the magnetic properties of the nanocomposites. FTIR identification analysis revealed that the chitosan/pluronic F127 were successfully immobilized on the surface of MRGO. Furthermore, α-mangosteen, as a model of natural drug compound, was successfully encapsulated onto the chitosan/pluronic F127@MRGO nanocomposites. According to in-vitro cytotoxicity assay, α-mangosteen-loaded chitosan/pluronic F127@MRGO nanocomposites could significantly reduce the proliferation of human breast cancer (MFC-7) cells. Eventually, it would be anticipated that the novel α-mangosteen-loaded chitosan/pluronic F127@MRGO nanocomposites could be promoted as a new potential material for magnetically targeting and killing cancer cells.

show abstract